{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-117678","form_type":"8-K","ticker":"BCLI","cik":"0001137883","company_name":"BRAINSTORM CELL THERAPEUTICS INC.","filed_at":"2023-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.327884+00:00","generated_at":"2026-06-08T03:12:44.070407+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Brainstorm reports Q3 net loss $1.2M; withdraws NurOwn BLA for ALS, cuts 30% headcount","bullets":["Withdrew BLA for NurOwn in ALS after FDA advisory committee vote; FDA invites expedited meeting for path forward.","Strategic realignment reduces headcount ~30%, targets cutting total resource consumption by half.","Cash, equivalents, and short-term deposits at $1.4M as of Sep 30, 2023, down from $3M at Dec 31, 2022.","Net loss for Q3 2023 was $1.2M ($0.03 per share) vs. $6.9M ($0.19 per share) in Q3 2022.","Raised ~$7.5M gross in July 2023 registered direct offering with a single institutional investor."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-117678","json":"https://secwatch.observer/filing/0001104659-23-117678.json","markdown":"https://secwatch.observer/filing/0001104659-23-117678.md","text":"https://secwatch.observer/filing/0001104659-23-117678.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923117678/0001104659-23-117678-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923117678/tm2330690d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T03:12:44.070407+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be911f7ab458421f7aa075d9352c9bfaae83ab55","claim":"BRAINSTORM CELL THERAPEUTICS INC. reported the quarter ended September 30, 2023 results: net income Net loss for the three months ended September 30, 2023 was approximately $1.2 million, EPS Net loss per share for the three months ended September 30, 2023 and 2022 was $0.03 and $0.19, respectively.","evidence_excerpt":"BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1137883/000110465923117678/0001104659-23-117678-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss for the three months ended September 30, 2023 was approximately $1.2 million"},{"label":"EPS","value":"Net loss per share for the three months ended September 30, 2023 and 2022 was $0.03 and $0.19, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}